2021 is fleeting, unknowingly entering the last month. It is approaching the most eagerly awaited moment for cancer patients every year, and the results of health care negotiations in 2021 are hot.
On December 3, according to the CCTV news client, the National Medical Security Bureau held a press conference to announce the adjustment results of the national medical insurance drug catalogue in 2021. A total of 74 drugs were added to the catalogue, and 11 drugs were transferred out of the catalogue.
From the perspective of negotiation, 67 kinds of exclusive drugs outside the catalogue were successfully negotiated, with an average price reduction of 61.71%. At present, the total number of drugs in the national medical insurance drug catalogue in 2021 is 2860, which will be implemented on January 1, 2022.
In 2021, the latest medical insurance catalog included 18 new anti-cancer drugs, covering a wide range, including non-small cell lung cancer, lymphoma, breast cancer, ovarian cancer, liver cancer, gastric cancer, myeloma, prostate cancer, neuroendocrine tumors and many other cancers. For cancer patients, there are many patients waiting for life-saving new drugs!
In 2021, 18 types of anti-tumor drugs entering medical insurance
Looking back on the past three years, the health care negotiation has achieved remarkable results. More than 200 new drugs have been included. Through the negotiation, the price of drugs has been greatly reduced and the accessibility of drugs has been improved. Both varieties with better competition pattern and varieties with relatively fierce competition can achieve rapid volume after being incorporated into medical insurance through negotiation, bringing income and profit growth space to corresponding varieties.
Source: globecancer.com
http://www.globecancer.com/azzx/show.php?itemid=14620
